Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus PROQUIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus PROQUIN XR.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs PROQUIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
400 mg intravenously every 8-12 hours over 60 minutes.
500 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 10-14 hours in patients with normal renal function (CrCl >80 mL/min). Extended half-life may occur in renal impairment, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Primarily renal excretion of unchanged drug (~60-80%) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 20-35%, with a small portion as metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic